ReviewInternational journal of molecular sciences2021
Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Integrative bibliometrics and spatial transcriptomics identify CAF-associated genes and immune niches in hepatocellular carcinoma.Discover oncology · 2026Article
- Review
- Prediction of Tumor Progression After Microwave Ablation of Hepatocellular Carcinoma by Contrast-Enhanced Ultrasound Combined with Immunohistochemical Markers.Journal of hepatocellular carcinoma · 2026Article
- Identification of novel small molecule inhibitors targeting multiple methyltransferase like proteins against hepatocellular carcinoma.Scientific reports · 2025Article
- Identification of a cancer stem cell-like subpopulation that promotes HCC metastasis.JHEP reports : innovation in hepatology · 2025Article
- Article
- M2BPGi Correlated with Immunological Biomarkers and Further Stratified Recurrence Risk in Patients with Hepatocellular Carcinoma.Liver cancer · 2025Article
- Article
- Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy.Cancer medicine · 2024Review
- Evaluation of the efficacy of transarterial chemoembolization combined with microwave ablation followed by adjuvant therapy in patients with hepatocellular carcinoma.Frontiers in immunology · 2024Article
- Article
- Updates and Expert Opinions on Liver Transplantation for Gastrointestinal Malignancies.Medicina (Kaunas, Lithuania) · 2023Review
- Review
- An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation.International journal of molecular sciences · 2023Review
- Adjuvant TACE may not improve recurrence-free or overall survival in HCC patients with low risk of recurrence after hepatectomy.Frontiers in oncology · 2023Article
- Clinical Results, Risk Factors, and Future Directions of Ultrasound-Guided Percutaneous Microwave Ablation for Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2023Review
- Intra-tumor heterogeneity and prognostic risk signature for hepatocellular carcinoma based on single-cell analysis.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Serum T Cell Immunoglobulin Mucin 3 Predicts Worse Prognosis in Hepatocellular Carcinoma Patients Undergoing Transcatheter Arterial Chemoembolization.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- HIF-2α regulates proliferation, invasion, and metastasis of hepatocellular carcinoma cellsFrontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortalities worldwide. Patients with early-stage HCC are eligible for curative treatments, such as surgical resection, liver transplantation (LT) and percutaneous ablation. Although curative treatments provide excellent long-term survival, almost 70-80% of patients experience HCC recurrence after curative treatments. Tumor-related factors, including tumor size, number and differentiation, and underlying liver disease, are well-known risk factors for recurrence following curative therapies. Moreover, the tumor microenvironment (TME) also plays a key role in the recurrence of HCC. Many immunosuppressive mechanisms, such as an increase in regulatory T cells and myeloid-derived suppressor cells with a decrease in cytotoxic T cells, are implicated in HCC recurrence. These suppressive TMEs are also modulated by several factors and pathways, including mammalian target of rapamycin signaling, vascular endothelial growth factor, programmed cell death protein 1 and its ligand 1. Based on these mechanisms and the promising results of immune checkpoint blockers (ICBs) in advanced HCC, there have been several ongoing adjuvant studies using a single or combination of ICB following curative treatments in HCC. In this review, we strive to provide biologic and immunological markers, prognostic factors, and challenges associated with clinical outcomes after curative treatments, including resection, LT and ablation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.